Products
Cinacalcet is commercially available in the form of film-coated tablets (Mimpara, some countries: Sensipar). It has been approved in many countries since 2004. Generic versions were registered in 2016.
Structure and properties
Cinacalcet (C22H22F3N, Mr = 357.4 g/mol) is present in drugs as cinacalcet hydrochloride, a white crystalline powder that is sparingly soluble in water. The -enantiomer that is predominantly active is used.
Effects
Cinacalcet (ATC H05BX01) has calcimimetic properties. It lowers parathomone levels by increasing the sensitivity of the calcium-sensing receptor (CaR) to extracellular calcium at the parathyroid gland. This also lowers serum calcium levels. Cinacalcet has a long half-life of up to 40 hours.
Indications
- Secondary hyperparathyroidism in dialysis-dependent patients with chronic kidney disease.
- Hypercalcemia in patients with parathyroid carcinoma and in patients with primary hyperparathyroidism.
Dosage
According to the professional information. The film-coated tablets are taken with or shortly after a meal.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Cinacalcet is metabolized by CYP3A4, CYP2D6, and CYP1A2 and is an inhibitor of CYP2D6. Corresponding drug-drug interactions are possible.
Adverse effects
The most common potential adverse effects include nausea, vomiting, and muscle cramps.
